Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Purchases $1,000,073.36 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Todd Davis bought 35,948 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the transaction, the director owned 75,834 shares in the company, valued at approximately $2,109,701.88. This represents a 90.13% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Pelthos Therapeutics Stock Performance

PTHS opened at $27.01 on Thursday. The business’s 50 day simple moving average is $25.43. The firm has a market cap of $93.99 million, a P/E ratio of -1.31 and a beta of 3.16. Pelthos Therapeutics Inc. has a 1 year low of $11.20 and a 1 year high of $54.29. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The company had revenue of $10.91 million for the quarter. On average, sell-side analysts predict that Pelthos Therapeutics Inc. will post -11.7 earnings per share for the current year.

Institutional Trading of Pelthos Therapeutics

Several large investors have recently bought and sold shares of PTHS. Geode Capital Management LLC grew its position in Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after acquiring an additional 3,295 shares in the last quarter. Knott David M Jr grew its position in Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after acquiring an additional 13,169 shares in the last quarter. Persistent Asset Partners Ltd grew its position in Pelthos Therapeutics by 150.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after acquiring an additional 3,604 shares in the last quarter. Diadema Partners LP grew its position in Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares in the last quarter. Finally, Cantor Fitzgerald L. P. acquired a new stake in Pelthos Therapeutics in the fourth quarter valued at approximately $1,085,000. Institutional investors and hedge funds own 77.96% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on PTHS shares. Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 target price for the company. Roth Mkm dropped their target price on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Piper Sandler began coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They issued an “overweight” rating and a $48.00 price objective for the company. Oppenheimer increased their price objective on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Finally, Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $55.80.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).